Avient Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVNT research report →
Range $44 – $54
Price Chart
About the company
Avient Corporation, established in 1885 and based in Avon Lake, Ohio, is a global enterprise specializing in advanced material solutions, custom formulation services, and sustainable products. The company, which operated as PolyOne Corporation until its rebranding in June 2020, serves markets across the United States, Canada, Mexico, Europe, South America, and Asia. Its operations are divided into three primary business units: 1.
- CEO
- Michael J. Frank
- IPO
- 1999
- Employees
- 9,000
- HQ
- Avon Lake, OH, US
Get TickerSpark's AI analysis on AVNT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.95B
- P/E
- 21.85
- Fwd P/E
- 13.12
- PEG
- 0.37
- P/S
- 1.16
- P/B
- 1.61
- EV/EBITDA
- 10.52
- Div Yield
- 2.56%
- Gross Margin
- 32.14%
- Op Margin
- 9.75%
- Net Margin
- 5.32%
- ROE
- 7.52%
- ROIC
- 4.90%
Latest fiscal year · YoY change
- Revenue
- $3.26B+0.6%
- Gross Profit
- $1.06B+0.1%
- Op Income
- $203.50M
- Net Income
- $81.90M-51.7%
- EPS
- $0.90-51.6%
- OCF Growth
- +17.4%
- FCF Growth
- +44.6%
- Beta
- 1.25
- RSI (14)
- 49
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Avient beat expectations in Q3 with double-digit organic growth and margin expansion, and raised full-year profit, EBITDA, and cash-flow guidance while outlining a more aggressive growth and capital allocation agenda under its new CEO.· November 4, 2026
- Adjusted EPS was $0.86, $0.06 above expectations, with total company organic sales up 10.6% year over year.
- Adjusted EBITDA margin rose 80 basis points to a third-quarter record 17.3%, helped by pricing, mix, and productivity.
- Both segments grew strongly: Color Additives and Ink had 8% organic sales growth and SEM had 15% organic sales growth.
- Management raised 2026 guidance for adjusted EPS, adjusted EBITDA, and adjusted free cash flow, while keeping a balanced approach to debt paydown and buybacks.
- New CEO Mike Frank said the strategy is working, but he sees room to accelerate innovation scaling, cross-selling, and supply-chain optimization.
Q3 adjusted EPS was $0.86, which was $0.06 ahead of expectations. Total company organic sales increased 10.6% year over year, adjusted EBITDA margin expanded 80 basis points to 17.3%, adjusted EBITDA grew 16%, and adjusted EPS grew 23% versus the prior-year third quarter. Segmentally, Color Additives and Ink posted 8% organic sales growth and 120 basis points of EBITDA margin expansion to 20.1%, while Specialty Engineered Materials posted 15% organic sales growth and 140 basis points of EBITDA margin expansion to 21.3%. For 2026, Avient now expects adjusted EBITDA of $593 million to $603 million, adjusted EPS of $3.22 to $3.32, and adjusted free cash flow of $215 million to $230 million; capital spending is now expected to be approximately $120 million. The company also said it repaid $50 million of debt in Q3 and has repaid $250 million over the last 18 months, with net leverage expected to exit 2026 at 2.2x to 2.3x versus 2.6x at the end of 2025.
Mike Frank’s comments were upbeat and strategic, emphasizing that Avient has a strong business, a clear strategy, and momentum already showing up in the results. He framed his mandate as accelerating growth rather than turning the company around, pointing to faster innovation scaling, broader cross-selling, and supply-chain optimization as the main levers. He also stressed that growth should not come at the expense of margin discipline, and said he will focus on profitable sales growth, EBITDA margins, and free cash flow.
Joe DeSalvo said the quarter reflected broad-based strength, with pricing, new business wins, and demand in growth vectors driving 10.6% organic sales growth and 16% adjusted EBITDA growth. He highlighted that volume was only about 1% companywide, with the rest of organic growth coming from price and mix, and said the company benefited from higher-value products such as functional additives and barrier technologies. On capital and liquidity, he cited $50 million of Q3 debt paydown, total debt reduction of $250 million over 18 months, approximately $120 million of full-year capex, and 281 thousand shares repurchased for about $10.9 million so far in Q4.
Analysts focused on how quickly the new CEO can accelerate growth, whether Avient has under-scaled innovation in the past, and what the path is to a more meaningful capital deployment framework. Frank said this is not a correction but an acceleration effort, and that more detail on the 2027 operating plan will come with Q4 earnings in February. On M&A and buybacks, management said M&A is not near-term, the company is still rebuilding that muscle after years of deleveraging, and capital will likely be split among debt reduction, opportunistic repurchases, and other value-enhancing uses. On health care, management said inventory rebalancing is still affecting some drug-delivery areas, but underlying demand remains strong and long-term growth trends are intact.
The bull case from the call is that Avient is already delivering strong organic growth and margin expansion, with both segments and every region contributing in the quarter. Management sees durable upside from secular growth vectors such as health care, defense, electronics, and packaging, and believes the company can scale innovation faster and use its broad portfolio more effectively. The raised full-year guidance and first share repurchases since 2022 also suggest improving cash generation and greater capital flexibility.
The main risks discussed were macro uncertainty, persistent inflation, and higher interest rates, all of which management said remain part of the outlook. Europe was softer than other regions, and color volumes were slightly down overall because of muted demand there. Management also acknowledged that health care has had customer inventory rebalancing, and that meaningful M&A is not expected soon while the company continues to focus on deleveraging and rebuilding that capability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 91.75M
- Float Shares
- 91.10M
of shares held by institutions
353 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AVNT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Sep 2, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 17, 25 | Filing → |
| Thomas Richard CarperSenate · DE | Sell | Apr 17, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 21, 22 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jul 30, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.82M | ▲ 731.44K |
| Vanguard Group Inc | 10.22M | ▲ 77.25K |
| Vanguard Portfolio Management LLC | 5.69M | ▲ 186.41K |
| Dimensional Fund Advisors LP | 5.40M | ▲ 139.84K |
| Vanguard Capital Management LLC | 4.12M | ▲ 8.74K |
| State Street Corp | 3.96M | ▲ 116.37K |
| Alliancebernstein L.P. | 3.49M | ▲ 819.99K |
| Wellington Management Group Llp | 3.01M | ▲ 78.94K |
| Victory Capital Management Inc | 2.85M | ▲ 1.84M |
| Geode Capital Management, LLC | 2.49M | ▼ 17.84K |
| Invesco Ltd. | 2.17M | ▲ 188.22K |
| Channing Capital Management, LLC | 1.93M | ▼ 450.11K |
Held by 449 ETFs
Biggest fund positions in AVNT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 13, 26 | Frank Michael J | other | 126,455 |
| Oct 7, 26 | Frank Michael J | other | 0 |
| Sep 30, 26 | WULFSOHN WILLIAM A | other | 958 |
| Sep 30, 26 | Verduin Patricia | other | 958 |
| Sep 30, 26 | Preete Kerry J | other | 958 |
| Sep 30, 26 | Nicolas Ernest | other | 958 |
| Sep 30, 26 | Mink Kim Ann | other | 958 |
| Sep 30, 26 | Jellison William R | other | 958 |
| Sep 30, 26 | Green Neil | other | 958 |
| Sep 30, 26 | FEARON RICHARD H | other | 958 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVNT coverage
Recent articles, reports, and earnings notes.
No research on AVNT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVNT report →